NeoGenomics, Inc. (FRA:NG9)

NeoGenomics Statistics

Total Valuation

NeoGenomics has a market cap or net worth of EUR 1.34 billion. The enterprise value is 1.55 billion.

Market Cap	1.34B
Enterprise Value	1.55B

Important Dates

The next estimated earnings date is Friday, February 20, 2026.

Earnings Date	Feb 20, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	129.39M
Shares Outstanding	n/a
Shares Change (YoY)	+1.09%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	1.23%
Owned by Institutions (%)	94.47%
Float	119.43M

Valuation Ratios

PE Ratio	n/a
Forward PE	93.36
PS Ratio	2.21
PB Ratio	1.87
P/TBV Ratio	79.34
P/FCF Ratio	n/a
P/OCF Ratio	114.68
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 223.29, with an EV/FCF ratio of -106.64.

EV / Earnings	-16.02
EV / Sales	2.54
EV / EBITDA	223.29
EV / EBIT	n/a
EV / FCF	-106.64

Financial Position

The company has a current ratio of 3.91, with a Debt / Equity ratio of 0.49.

Current Ratio	3.91
Quick Ratio	3.27
Debt / Equity	0.49
Debt / EBITDA	50.86
Debt / FCF	-24.07
Interest Coverage	-15.29

Financial Efficiency

Return on equity (ROE) is -12.99% and return on invested capital (ROIC) is -3.31%.

Return on Equity (ROE)	-12.99%
Return on Assets (ROA)	-3.03%
Return on Invested Capital (ROIC)	-3.31%
Return on Capital Employed (ROCE)	-5.72%
Revenue Per Employee	274,736
Profits Per Employee	-43,959
Employee Count	2,200
Asset Turnover	0.47
Inventory Turnover	15.17

Taxes

Income Tax	-444,901
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.57% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-34.57%
50-Day Moving Average	8.38
200-Day Moving Average	7.39
Relative Strength Index (RSI)	73.87
Average Volume (20 Days)	2,048

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.45

Income Statement

In the last 12 months, NeoGenomics had revenue of EUR 604.42 million and -96.71 million in losses. Loss per share was -0.76.

Revenue	604.42M
Gross Profit	262.34M
Operating Income	-62.27M
Pretax Income	-97.15M
Net Income	-96.71M
EBITDA	-2.93M
EBIT	-62.27M
Loss Per Share	-0.76

Balance Sheet

The company has 139.88 million in cash and 349.71 million in debt, giving a net cash position of -209.83 million.

Cash & Cash Equivalents	139.88M
Total Debt	349.71M
Net Cash	-209.83M
Net Cash Per Share	n/a
Equity (Book Value)	714.47M
Book Value Per Share	5.54
Working Capital	242.56M

Cash Flow

In the last 12 months, operating cash flow was 11.67 million and capital expenditures -26.20 million, giving a free cash flow of -14.53 million.

Operating Cash Flow	11.67M
Capital Expenditures	-26.20M
Free Cash Flow	-14.53M
FCF Per Share	n/a

Margins

Gross margin is 43.40%, with operating and profit margins of -10.30% and -16.00%.

Gross Margin	43.40%
Operating Margin	-10.30%
Pretax Margin	-16.07%
Profit Margin	-16.00%
EBITDA Margin	-0.49%
EBIT Margin	-10.30%
FCF Margin	n/a

Dividends & Yields

NeoGenomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.09%
Shareholder Yield	-1.09%
Earnings Yield	-7.23%
FCF Yield	-1.09%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NeoGenomics has an Altman Z-Score of 1.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.7
Piotroski F-Score	4